Company profile
Spexis
Spexis AG (SIX:SPEX) is a clinical-stage, publicly-listed biopharmaceutical company focused on discovering and developing first-in-class macrocyclic molecules for rare diseases and cancer. Spexis was created in December 2021 through the merger of EnBiotix, Inc., a privately held US biotech, into Polyphor AG, a publicly listed Swiss biotechnology company.
Source: startup.ch
